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Beyond the pill: new medication delivery options
for ADHD
Andrew J. Cutler1* and Gregory W. Mattingly2,3
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Successful treatment of pediatric disorders has necessitated the development of alternative medication formulations, as
children may prefer alternative dosage forms to tablets or capsules. This is especially true for attention-deficit/
hyperactivity disorder (ADHD), which is one of the most common chronic pediatric conditions and often involves
children with a variety of overlapping physical, psychological, or neurodevelopmental disorders. A special challenge for
developing alternative dosage forms for ADHD treatment is the incorporation of a once-daily long-acting formulation.
Traditional ADHD medication formulations have been limited, and issues surrounding prescribed dosing regimens—
including poor medication adherence, difficulty swallowing, and the lack of dosing titration options—persist in ADHD
treatment. In other disease areas, the development of alternative formulations has provided options for patients who
have issues with consuming solid dosage forms, particularly children and individuals with developmental disorders.
In the light of these new developments, several alternative formulations for ADHDmedications are under development
or have recently become available. This article reviews the various strategies for developing alternative dosage forms in
other disease areas and discusses the application of these strategies in ADHD treatment. Alternative dosage forms
may increase medication adherence, compliance, and patient preference and, therefore, improve the overall treatment
for ADHD.
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Introduction
For the successful treatment of pediatric diseases,
delivering medication via formulations that are accep-
table to children is a recommended strategy to improve
therapeutic outcomes.1 Given that many medications are
formulated as capsules and tablets, the development of
alternative formulations is important because children
may prefer options other than solid oral dosage forms.2,3
This is particularly relevant to attention-deficit/hyper-
activity disorder (ADHD), one of the most common
pediatric conditions, which often involves children with
a variety of overlapping physical, psychological, and
neurodevelopmental disorders.
ADHD is a chronic psychiatric disorder characterized
by inattention, hyperactivity, and impulsivity.4–6 In the
US, ADHD has been reported to affect∼6–8% of children
(in comparison to about a 10% prevalence of asthma in
school-aged children7) and 4.4% of adults.8,9 Approxi-
mately 95% of ADHD patients are diagnosed before the
age of 12, and up to 60% of them continue to meet the
diagnostic criteria for ADHD as adults.9 Selection of an
ADHD treatment approach is dependent on a patient’s
age and the severity of the disease.5,6,10 Behavioral
therapies are the first-line option recommended for
preschool-aged children, and pharmacologic agents are
often the first-line option for school-aged children and
adults, particularly for those with moderate to severe
impairment.10–12 Pharmacotherapy has been proven to
be very effective in patients of all ages. Practice guide-
lines recommend the central nervous system stimulants
methylphenidate (MPH) and amphetamine (AMP) as
first-line ADHD medications because of their proven
efficacy in reducing ADHD core symptoms in both
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children and adults.4,5,13–15 While some patients may
preferentially respond to or tolerate one better
than the other, both stimulant classes are considered
appropriate first-line interventions until efficacy and
tolerability can be assessed in an individual patient.4
Nonstimulant medications are also indicated for treating
ADHD, but they are not as effective as stimulants and,
therefore, are recommended as a second-line treatment
or adjuvant therapy.5,16
Most ADHD medications are formulated as solid
tablets or capsules that need to be taken daily,17 which
poses a potential challenge for children who experience
difficulties swallowing pills or for individuals with autism
or other developmental disabilities who may have tactile
issues that preclude the use of tablets, capsules, or even
sprinkled preparations.18–20 For example, ∼46–89% of
children with autism-spectrum disorders have feeding
disorders, raising significant concerns for ingesting solid
oral formulations.21,22 Chewing or crushing pills to ease
ingestion may alter the pharmacokinetics of the medica-
tions and is inadvisable for most stimulants.23 Although
short-acting liquid formulations of stimulants have long
existed,24 long-acting alternative dosage formulations
have only recently become available and include liquid
suspensions, chewable tablets, and orally disintegrating
tablets (ODTs).25–29 Additionally, the only option for a
non-oral route of administration is a transdermal-patch
system.30 Despite their proven effectiveness, adherence
to ADHD stimulants is poor across patients of all age
groups for various reasons,31,32 and difficulty swallowing
or an aversion to oral tablets may be a barrier to ADHD
treatment.18,19 Alternative oral dosage forms, especially
those in long-acting formulations with reduced dosing
frequencies, may ease medication delivery and improve
outcomes for patients. However, incorporating a once-
daily long-acting formulation into alternative dosage
forms can be challenging.
Alternative oral formulations that ease ingestion in
children have been successfully established for treating
conditions that commonly occur in children, such as
bacterial infections, pain, and allergies. Some examples
include fruit-flavored liquid amoxicillin, loracarbef,
and doxycycline solutions;33 ibuprofen oral liquid
suspension, chewable tablets, and ODTs;34,35 and sub-
lingual formulations for allergy and asthma allergen
immunotherapy.36–38 Other than ease of ingestion, these
formulations may possess additional advantages over
their capsule or tablet counterparts, such as a more
favorable pharmacokinetic profile or improved safety.
Beyond pediatric care, alternative oral dosage forms
have also demonstrated benefits in many chronic dis-
ease areas—including cardiovascular, dyslipidemia, and
chronic pain.39 However, most of the alternative dosage
forms are short-acting formulations that require multiple
daily doses.3 With advances in technology, long-acting
transdermal patches, oral liquid solutions, and ODTs
with reduced dosing frequencies are emerging, such
as buprenorphine extended-release (ER) transdermal
patches, azithromycin oral suspension, and ketopro-
fen orally disintegrating/sustained-release tablets,40–43
which may further facilitate medication administration.
Alternative Dosage Forms for the Management of
Psychiatric Disorders
Alternative oral dosage forms, such as chewable tablets,
liquid solutions, sublingual tablets, and ODTs have been
developed for the treatment of psychiatric disorders.44,45
Aside from obviating swallowing difficulties, each oral
dosage form provides unique benefits.3,40,44,46 Liquid
agents can be accurately split into a flexible dose, enabling
gradual dose adjustment.40 The sublingual route of
administration avoids first-pass metabolism, resulting in
quicker absorption and onset of effect as compared
to other oral delivery methods.45 The use of ODTs
may enhance compliance not only in individuals with
swallowing or tactile issues but also in pill-averse patients
who willfully refuse medication, as ODTs disintegrate
rapidly after administration and prevent surreptitious
behaviors, such as cheeking, pouching, or spitting pills
out.47 The ODT formulation may also reduce misuse of
psychotic medications (e.g., stimulants) that can have the
potential for abuse, misuse, or diversion.45
Different dosage forms may also affect patients’
adherence to their medications. Like many chronic
disease areas in which medication discontinuation is
common, such as diabetes (adherence=31–87%, depending
on the study48) and hypertension (adherence ∼50%49),
medication adherence in patients with psychiatric
disorders is also suboptimal, ranging from 40 to
60%.50,51 Psychiatric medications in liquid, sublingual,
or ODT forms improve adherence compared with
standard tablets.51 In addition, simplifying medication
regimens has a positive effect on adherence in patients
with psychiatric disorders.52,53 Long-acting formulations
have been shown to enhance medication adherence in
the management of depression,54 Parkinson’s disease,55
and dementia.56
The benefits of ODTs in psychiatric treatment have
been documented in studies of olanzapine, an antipsy-
chotic medication indicated for the treatment of schizo-
phrenia and bipolar I disorder.47 Clinical studies indicate
that olanzapine formulated as an ODT is as effective as
the standard tablet formulation,57–59 but 61% of patients
opted for ODTs versus 27% for standard tablets in a
study, suggesting that ODTs are a patient-preferred
formulation.57 Furthermore, olanzapine ODT has
significantly improved medication adherence59 and
reduced caregiver burden because of high patient
acceptance.58–60 Other examples of alternative oral
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dosage forms in psychiatric treatment include risper-
idone and aripiprazole ODTs for treating schizophrenia
and bipolar disorder,45 risperidone oral solution for
treating schizophrenia,61 mirtazapine ODT for treating
depression,62 asenapine sublingual tablets for treating
schizophrenia and bipolar mania,63 and benzodiazepine
(e.g., alprazolam, lorazepam, and clonazepam) ODTs for
treating anxiety, depression, and panic disorder.64–66
ODTs have consistently demonstrated advantages of easy
ingestion and high patient preference across different
classes of medications.62,64,66
Formulations of Stimulants for Treating ADHD
The success of alternative oral formulations has been
well-established in psychiatric treatment, but alternative
oral formulations for ADHDmedications are still limited.
The stimulants for ADHD treatment, methylphenidate
and amphetamine, are available in a variety of formula-
tions67 (Tables 1 and 2). Although methylphenidate and
amphetamine have demonstrated similar efficacies at the
population level, individual patients may respond better
to one or the other.4,5 Thus, the choice as to which
stimulant to prescribe depends on factors such as
treatment history and patient and prescriber prefer-
ence.13,68 Owing to their short halflives, first-generation
stimulants were short-acting (or immediate release)
medications.69 Short-acting methylphenidate and
amphetamine typically take effect within 30 minutes
after dosing, with durations of action ranging from 3 to
6 hours.70–72 Thus, they require 2 to 4 doses a day to
provide 12-hour symptom control.70,71 Despite the
proven effectiveness of short-acting stimulants,69,72,73
the need for multiple daily dosing may lead to fragmen-
ted treatment coverage, missed doses, and social stigma
for school-aged children, along with liability concerns
regarding in-school medication storage due to dosing
requirements during school hours.72,74,75
Long-acting (or ER) methylphenidate and ampheta-
mine formulations have been developed to overcome the
issues caused by frequent dosing associated with short-
acting stimulants. Some long-acting stimulants contain
two compartments or different populations of beads that
release medication at different speeds, providing both
rapid onset of action and long-lasting treatment effects;
while others are prepared in a controlled-release
formulation that delivers the active ingredient under
osmotic pressure at a controlled rate throughout the
day.76,77 In addition, one long-acting amphetamine
formulation is supplied as an inactive prodrug, lisdex-
amfetamine, which is converted to active amphetamine
after being absorbed from the gastrointestinal tract.78
Long-acting stimulants are designed for patients to take
once daily in the morning, with symptom control lasting
for 8 to 12 hours.68,72,76 Clinical studies have demon-
strated that once-daily long-acting stimulants are as
effective as multiple-dosed short-acting stimulants in
reducing ADHD core symptoms and improving cognitive
skills in both children and adults.75,79–81 Insurance claim
data suggest that ADHD children who received long-
acting stimulants were less likely to visit an emergency
department or become hospitalized than those receiving
short-acting stimulants.82 Compared with short-acting
stimulants, the advantages of long-acting stimulants
include simpler dosing, reduced stigma related to
medication use, reduced burden on schools regarding
medication storage, and improved adherence.71,83–85
In addition, long-acting stimulants have a smoother
pharmacokinetic profile, with reduced fluctuation in
plasma medication concentrations compared with their
short-acting counterparts, which may prevent euphoria
and rebound effects.71 Furthermore, stimulants are
controlled substances that have the potential for
diversion and abuse.86,87 Long-acting stimulants are
associated with lower rates of misuse or abuse than their
short-acting counterparts because their use does not
correlate as strongly with euphoria and it is more
difficult to extract active drug ingredients.83,87,88 Several
long-acting alternative formulations of stimulants have
recently become available, including liquid suspensions,
chewable tablets, and ODTs.25,26,29 While the extent to
which a formulation affects adherence to ADHD
medication regimens remains to be investigated, the
potential for better treatment individualization through
the development of alternative dosage forms may
improve outcomes in patients with ADHD.
Poor medication adherence in ADHD treatment
Analyses of insurance claims have revealed that medica-
tion adherence rates among ADHD patients are about
50% in the first year, but the rates decrease considerably
over time (32.8% at 2 years; 17.2% at 5 years).32 On
average, children and adults only strictly adhere to their
initially prescribed dosing regimens for 34.2 and
49.5 days, respectively, although they may continue with
their medications on compromised schedules or doses
for approximately 200 days.31 These studies were based
on claim data from 2008 or earlier, when most ADHD
medications were likely to be short-acting agents.
Later analyses of data, including both short- and long-
acting ADHD medications, demonstrated an approximate
24–30% increase in adherence for long-acting medications
compared with their short-acting counterparts.84,85 The
reasons for poor medication adherence in ADHD include
side effects, ineffectiveness, lack of insight into the
disease, dosing inconvenience, social stigma, and costs.67
Specific reasons for medication nonadherence vary
among patients of different age groups. Children often
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TABLE 1. Summary of short-acting and long-acting methylphenidate24-26,29,76,103,104,106,107,109,111,115–119
Product name Formulation Daily dosage Tmax (mean, hours) T1/2 (mean, hours)
Standard capsules or tablets
Concerta® (methylphenidate hydrochloride extended-release tablets) Tablet, ER 1 Initial peak at 1; second peak at 6–10 3.5a
Focalin® (dexmethylphenidate hydrochloride tablets) Tablet 2 1–1.5 2.2
Metadate ER® (methylphenidate hydrochloride extended-release tablets) Tablets, XR 1 4.7b N/A
Methylin ER™ (methylphenidate hydrochloride extended-release tablets) Tablet, ER 2–3 Initial peak at about 1; the second peak at 6–10 3.5a
Ritalin® (methylphenidate hydrochloride tablets) Tablet 2–3 1.9a or 1.8b 3.5a or 2.5b
Ritalin-SR® (methylphenidate hydrochloride sustained-release tablets) Tablet, ER 2–3 3.4a or 4.7b 4.1a
Capsules that can be sprinkled on foods
Aptensio XRTM (methylphenidate hydrochloride extended-release capsules) Capsule, ER 1 Initial peak at 2; second peak at 8a 5.09a,c or 5.43a,d
Focalin XR® (dexmethylphenidate hydrochloride extended-release capsules) Capsule, ER 1 Initial peak at 1.5; second peak at 6.5a 3a or 2–3b
Metadate CD® (methylphenidate hydrochloride extended-release capsules) Capsule, ER 1 Initial peak at 1.5; second peak at 4.5c,e 6.8a
Ritalin LA® (methylphenidate hydrochloride extended-release capsules) Capsule, ER 1 Initial peak at 2; second peak at 5.5a or 6.6b 3.3a or 2.4b
Transdermal patch
Daytrana® (methylphenidate transdermal system) Transdermal patch, ER 1 10f 4–5.b,g 1.4–2.9b,h
Chewable tablets
MethylinTM (methylphenidate hydrochloride chewable tablets) Chewable tablet 2–3 1–2 3a
Quillichew ER™ (methylphenidate hydrochloride extended-release chewable tablets) Chewable tablet, ER 1 5i 5.2
Oral solutions
MethylinTM (methylphenidate hydrochloride oral solution) Oral solution 2–3 1–2 2.7a
Quillivant XR® (methylphenidate hydrochloride for extended-release oral suspension) For suspension, ER 1 4 5.2
ER= extended release; N/A= not applicable; T1/2= halflife; Tmax= time to peak plasma concentration.
a In adults.
b In children.
c Capsule.
d Sprinkle.
e 25–30% of subjects had only one observed peak.
f 8 after repeat patch applications when worn up to 9 hours.
g d-methylphenidate.
h l-methylphenidate.
i Median.
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discontinue medications under their parents’ or care-
givers’ discretion because of side effects, high medication
costs, denial of illness, and difficulty swallowing.17,67,89
Together, the need for school-aged children, especially
those taking short-acting stimulants, to go to the nurse’s
office for dosing during school hours, which can lead to
unwanted social stigma, and liability issues related to
school storage of controlled medications may discourage
medication adherence.71,74,75 Parents and caregivers play a
critical role in medication adherence.17 A family history of
ADHD (especially parental) is associated with decreased
adherence,17 possibly because of ADHD symptoms in the
adult, such as forgetfulness and difficulty managing the
child’s medication regimen. Fears about the long-term
risks or drug abuse associated with stimulant use
may be another reason that affects adherence,17,74,89
although these risks are low when medications are used
appropriately. Disagreement between parents about their
children’s need for medication could also impact medica-
tion use.89 This may be particularly relevant for children
with ADHDwho split time with their separated or divorced
parents, only one of whom supports use of the medication.
Additionally, perceiving ADHD as a parenting problem
rather than as a disease with biological origins may lead to
resistance to medication therapy and inadequate parental
supervision of medication adherence.90,91
Adolescents are generally less willing to use ADHD
medications than children and adults because of their
growing autonomy and rebelliousness.17,19,92,93 Accord-
ing to interviews with ADHD patients between ages
11 and 16 years, some patients felt that medications
deprived them of their self-identity and “gained control
over them.”19 As adolescents become older and more
involved in treatment decision making, they may
deliberately stop taking their medications.19 Other
common reasons for medication discontinuation in this
population include high medication costs, denial of
illness, lack of insight, and forgetfulness.19,67,92,94
Among adults with ADHD, side effects, high medica-
tion costs, and forgetfulness are the most commonly
reported reasons for medication nonadherence.19,67
Additionally, lack of insight—not viewing ADHD as a
disease with a biological basis—and negative attitudes
toward pharmacotherapy, such as fear of side effects and
loss of authentic self, may also prevent patients from
adhering to their medication regimens.19,67,93
TABLE 2. Summary of short- and long-acting amphetamine27,28,105,116,118,120–122
Product name Formulation Daily
dosage
Tmax (mean,
hours)
T1/2 (mean, hours)
Standard capsules or tablets
Adderall (amphetamine mixed salts tablets)a Tablets 1–3 3 10–11.b 12–14c
Desoxyn® (methamphetamine hydrochloride tablets) Tablet 1–2 NR 4–5
Dexedrine® (dextroamphetamine sulfate Spansule® sustained-release
capsules)
Tablet, ER 1–2 3 12
EvekeoTM (amphetamine sulfate tablets) Tablet 1–3 NR 10
Capsules that can be sprinkled on foods
Adderall XR® (amphetamine mixed salts capsules)a Capsule, ER 1 7 10.b,d 11.b,e or 9,b,f; 10.c,d 13–14,c,e 11c,f
Orally disintegrating tablets
Adzenys XR-ODT™ (amphetamine extended-release orally disintegrating
tablets)
ODT, ER 1 5,b,g 5.25c,g 11,b,d 9–10b,f;
14,c,d 10–11c,f
Oral solutions
Dyanavel™ XR (amphetamine extended-release oral suspension) Oral suspension,
ER
1 4 12,b 15c
ProCentra® (dextroamphetamine sulfate oral solution) Oral solution 1–2 NR 11.75
Prodrug capsules
Vyvanse® (lisdexamfetamine dimesylate capsules) Capsule 1 1,f,h 3,f,i 5b,g 1,h 11.6b
ER= extended release; NR= not reported; ODT= orally disintegrating tablets; T1/2= halflife; Tmax= time to peak plasma concentration.
a Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate.
b d-amphetamine.
c l-amphetamine.
d In adults.
e In adolescents.
f In children.
g Median.
h Lisdexamfetamine.
i Dextroamphetamine.
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Using long-acting stimulants improves medication
adherence. Clinical studies based on patient self-reports,
pill counts, and claims analyses have shown that long-
acting stimulants significantly improve adherence in
both children and adult patients with ADHD compared
to short-acting stimulants.17,90,95–97 For nonadherent
ADHD patients who have been on short-acting medica-
tions, switching to long-acting formulations enhances
medication adherence.16,98 The once-daily long-acting
formulations simplify dosing regimens and avoid the
social stigma caused by administration in public or at
school. The convenience and improved patient accep-
tance offered by long-acting stimulants may account for
the increased adherence.96
Difficulty swallowing
Difficulty swallowing represents a significant barrier
to pharmacotherapy.99,100 A wide variety of medical
conditions, such as stroke, cancer, neurological dis-
orders, connective tissue diseases, and gastroesophageal
reflux disease, can lead to swallowing difficulties.101 In
addition, many adults without conditions affecting their
ability to swallow have difficulty swallowing and express
a preference for formulations that eliminate swallowing
pills or capsules.2,100
Pediatric patients are more likely to encounter
difficulties in swallowing solid dosage forms than
adults.2,100 A survey of 304 parents with children aged
0 to 26 years (less than 1% over age 21) reported that
more than 50% of the children were unable to swallow a
standard-sized pill or a small capsule.2,102 In addition to
physical inabilities, children may refuse to ingest pills
because of conditioned anxiety associated with repeated
negative experiences, such as aversive medication taste
and fear of gagging.18 Parents may resort to cajoling,
threatening, or crushing and mixing medications in food
to improve adherence, potentially altering medication
pharmacokinetics and negatively affecting efficacy and
safety and causing distress in children.18 Adults who
experience difficulties swallowing often complain about
large pill size, sticky pill texture, and bad taste or smell of
medications.99,100 Common approaches used to address
this issue include drinking more water, opening
capsules, splitting or crushing pills, mixing contents
with food, tilting the head backward when swallowing,
and switching to a different dosage form.99,100 However,
crushing tablets and capsules may result in inaccurate
dosing.100
Difficulty swallowing is a common issue in treatment
and can affect medication adherence in ADHD patients
of all ages;74 therefore, several techniques have been
developed to ease pill ingestion. Some stimulant dosage
forms allow patients to open the capsule and sprinkle the
contents on applesauce (Metadate CD®, Ritalin LA®,
Adderall XR®, Aptensio XRTM, Focalin XR®) or in
yogurt, water, or orange juice (Vyvanse®).27,103–107
However, to ensure effectiveness and dosage accuracy,
the entire contents of the capsule need to be ingested
without being chewed.103–105 Among children with
ADHD or autism, swallowing training by encouraging
the swallowing of mock pills of increasing size has
resulted in successful pill ingestion.18 In other pediatric
disease areas, such swallowing exercises as modeling-
based behavioral intervention, swallowing technique
instructions, and coating the back of the mouth and
tongue with flavored spray have demonstrated effective-
ness.2 These strategies may also reduce barriers to
ADHD treatment.
The need for treatment individualization
Evidence-based ADHD guidelines recommend that
medication regimens should be tailored to the indivi-
dual, as each patient may differ in their response to or
tolerability of distinctive medications.68 In efforts to
optimize patient outcomes, clinicians should consider
both medication class (stimulants vs. nonstimulants and
types of stimulants/nonstimulants) and formulation.68
The selected formulation should not only provide
effective pharmacokinetic and pharmacodynamic pro-
files but also satisfy the patient’s/family’s preferences.
For example, patients who frequently travel may opt
for a dosage form that is easy to carry and can be
taken without water.47 In addition, practice guidelines
recommend medication dose titration for individual
ADHD patients to achieve an optimal dose with minimal
side effects while retaining therapeutic effectiveness.5
Overview of New Stimulant Formulations
In ADHD management, multiple medication and
formulation options better enable treatment individuali-
zation, leading to more favorable responses and
increased patient satisfaction. Because the majority of
treated ADHD patients are children who may be more
sensitive to medication texture and tastes and dislike
certain flavors,3,108 selection of a specific favored dosage
form may enhance their adherence to medications.3
To satisfy the need, several alternative stimulant
dosage forms are under development or have become
available, including a transdermal system,30 a long-acting
chewable tablet,25 liquid suspensions,26 and ODT
formulations.29
Daytrana® (Noven Therapeutics LLC, Miami, FL) is a
long-acting methylphenidate transdermal patch that
received FDA (U.S. Food and Drug Administration)
approval in 2006.109 This patch is applied to the hip
area 2 hours before the treatment effect is needed and
can be worn for up to 9 hours.30,109 In three randomized,
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double-blind, placebo-controlled studies conducted in
children or adolescents, daily 9-hour usage of Daytrana
provided significantly better ADHD symptom control
than placebo. Most side effects associated with Daytrana
are consistent with those of oral methylphenidate, except
for application site reactions, which are specifically
related to this formulation.109 Transdermal methylphe-
nidate not only precludes the need for swallowing pills
but also provides flexibility in adjusting the duration
of drug exposure, as the treatment effect can be dis-
continued simply by removing the patch.110 Because
transdermal methylphenidate avoids first-pass meta-
bolism and releases the active ingredient continuously,
it provides a smoother pharmacokinetic profile than oral
dosage forms, including some ER oral formulations that
have a biphasic drug release.110
Two liquid dosage forms of long-acting stimulants
have recently become available, including a methylphe-
nidate oral suspension, Quillivant XR® (Pfizer Inc.,
New York), approved in 2012, and an amphetamine
oral suspension, Dyanavel™ XR (Tris Pharma Inc.,
Monmouth Junction, NJ), approved in 2015.26,28
Quillivant XR is supplied as a powder that needs to be
reconstituted with water prior to dispensing. This agent
is dosed once daily in the morning, with the treatment
effect taking place within 45 minutes and lasting for
12 hours. In a laboratory classroom study, Quillivant XR
demonstrated superior efficacy in controlling ADHD
symptoms compared with placebo.26 Dyanavel XR is
supplied as a ready-for-use oral suspension dosed once
daily in the morning.28 The efficacy of Dyanavel XR has
been demonstrated in a laboratory classroom study in
which Dyanavel XR provided a significant improvement
in ADHD symptoms compared with placebo.28 Liquid
dosage forms of long-acting stimulants may represent an
appealing option for patients who experience difficulties
swallowing pills and who require gradual dose titration
or precise doses in between the doses available in solid
formulations to achieve optimal treatment effect and
tolerability.
Although a short-acting methylphenidate chewable
tablet (Methylin® chewable tablet, Shionogi Inc.,
Florham Park, NJ) has been on the market for years,111
long-acting methylphenidate chewable tablets were
unavailable until very recently.25 Quillichew ER™ (Pfizer
Inc., New York) is an ER chewable tablet that is dosed
once daily in the morning.25 While the prescribing
information recommends an initial dose for Quillichew
ER, patients receiving this medication may undergo dose
titration based on their treatment requirements or
responses. To satisfy this need, Quillichew ER tablets
are functionally scored and supplied in multiple
strengths, which facilitates splitting tablets with accurate
doses. In a laboratory classroom study, a single dose of
Quillichew ER in the morning significantly improved
ADHD symptoms over placebo, with the treatment
effect lasting for over 8 hours.25 This formulation not
only circumvents the need for swallowing intact pills
but also appeals to patients who prefer to chew their
medications.
The first approved long-acting ODT stimulant
formulation is an amphetamine medication, Adzenys
XR–ODT™ (Neos Therapeutics Inc., Grand Prairie,
TX).29 Adzenys XR–ODT is dosed once daily in the
morning by placing the ODT on the patient’s tongue,
where it disintegrates in saliva and can be swallowed
without chewing or crushing. In several clinical studies
conducted in pediatric or adult patients, Adzenys XR–
ODT provided significantly better control of ADHD
symptoms than placebo.29 In addition, a long-acting
methylphenidate XR–ODT is under development. In
clinical studies, methylphenidate XR–ODT has shown
favorable pharmacokinetics and provided effective
ADHD symptom relief relative to placebo without
causing serious safety concerns.112,113 Long-acting ODTs
not only ease ingestion but also offer the convenience of
once-daily-dosing. Stimulants in chewable pills and
ODTs are also portable options, as they are more
compact and have no risk of leaking or spilling compared
with liquid agents and do not require water or other
liquids for ingestion.
Conclusions
ADHD is a common psychiatric disorder that typically
develops in childhood and usually persists into adult-
hood.9,114 For most ADHD patients, the primary treat-
ment is pharmacotherapy using stimulants, which are
commonly formulated as tablets or capsules.4–6,13 Solid
oral formulations may negatively affect medication
adherence in ADHD treatment because of dosing
inconvenience, patient discomfort, or difficulty swallow-
ing. Therefore, efforts to refine stimulant formulations
can potentially enhance adherence.31,32 Among ADHD
patients, long-acting stimulants have shown proven
effectiveness in improving medication adherence com-
pared with their short-acting counterparts.17,90,95–97
Alternative oral dosage forms, such as chewable
tablets, liquid solutions, and ODTs, may also increase
adherence rates, as shown in other disease areas.39
Among various oral dosage forms, ODTs represent a
particularly portable and convenient option to ease
ingestion as they obviate the need for carrying liquids.
To fulfill the need for alternative oral dosage forms in
ADHD treatment, several new ER formulations of
stimulants have recently become available, including a
methylphenidate ER liquid suspension,26 an ampheta-
mine ER liquid suspension,28 a methylphenidate ER
chewable tablet,25 and an amphetamine ER–ODT.29
Furthermore, a methylphenidate ER–ODT is under
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development.112,113 The long-acting alternative oral
dosage forms have combined advantages of dosing
convenience and easy ingestion, thereby potentially
improving medication adherence in ADHD patients.
However, ER formulations of amphetamine chewable
tablets and transdermal patches are still lacking.
Future development is directed toward creating more
long-acting alternative dosage forms for amphetamine and
nonstimulant medications. As more medication formula-
tions become available, clinicians will have more tools
to individualize treatment and improve the effectiveness of
pharmacotherapy for ADHD.
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